Divi’s Laboratories’ Market Value Tops 3 Trillion Rupees as Shares Jump 7%
Key Facts
Divi’s Laboratories’ market capitalization crossed 3 trillion rupees for the first time in trading on November 9, 2026, reaching 3.09 trillion rupees at 09:40 local time, according to Business Standard. The stock was up 5% at 11,656.75 rupees at that time, after rising during the session to a record 11,818 rupees. The move followed the company’s announcement of its second-quarter results on November 7; it did not coincide with the announcement. The company approved the unaudited results for the quarter and first half ended September 30 at a board meeting on that date. Profit and revenue increased from the year-earlier period, while the record market capitalization came as the stock’s rally continued.
In trading, the stock rose 7% on November 9 to a record, extending its 7.5% gain in the previous Muhurat trading session. The stock rose for 12 consecutive trading sessions through November 9, gaining a cumulative 32% over that period, according to Business Standard. At 09:40, the share price was 11,656.75 rupees on the Bombay Stock Exchange, with a market capitalization of 3.09 trillion rupees. These figures show that the threshold was crossed during the trading session, after the results announcement on November 7. The market move followed strong growth in the company’s business in the second quarter.
Basic earnings per share rose to 42.49 rupees in the quarter ended September 2026, from 25.97 rupees in the year-earlier period, according to the company’s filing with the National Stock Exchange of India. Revenue also grew across segments, with custom synthesis revenue rising 44% to 2,200 crore rupees. Nutraceuticals revenue increased 13% to 273 crore rupees, while generics revenue rose 4.3% to 1,050 crore rupees. Business Standard attributed the growth to healthy volumes across segments. The comparison shows that custom synthesis had the highest growth rate among the segments cited, while generics continued to expand at a slower pace.
Operating profit growth accelerated faster than segment revenue growth: EBITDA rose 76.4% to 1,566 crore rupees in the second quarter of fiscal 2027. The EBITDA margin climbed 989 basis points to 42.6%, while the gross profit margin improved 739 basis points to 67.9%, according to Business Standard. The report linked the wider margins to a larger contribution from custom synthesis and an improvement in the gross profit margin. The quarter’s performance therefore included not only higher revenue but also improved margins and operating profit. This coincided with higher earnings per share than a year earlier.
By contrast, the company recorded a foreign exchange gain of 24 crore rupees in the quarter ended September 30, 2026, compared with a gain of 63 crore rupees in the corresponding period of 2025, according to its filing with the National Stock Exchange. That means the foreign exchange gain recorded in the latest quarter was lower than a year earlier. The item does not change the fact that operating margins and segment revenue improved over the same period, according to the report. Business Standard, citing ICICI Securities, said pricing pressure in generics is likely to continue for a few more quarters. It also quoted the company as guiding for continued double-digit revenue growth while maintaining margins.
On upcoming projects, ICICI Securities said three large dedicated projects are in the validation stage, with one nearing commercialization. It added that the other two projects are expected to be commercialized over the next few quarters. Business Standard quoted the company as expecting continued double-digit revenue growth while maintaining margins, alongside generics pricing pressure that is expected to persist for a few more quarters. These details point to two different outlooks: custom synthesis projects are advancing toward commercialization, while pricing challenges continue in the generics segment. The results approved by the board on November 7 were unaudited and covered the second quarter and first half ended September 30, 2026.